Patients with pulmonary adenocarcinoma consulted the neurology department due to multiple initial symptoms of cerebral ischaemia. Examination of each patient revealed pulmonary embolism, the ...
Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat ...
Savara Inc. (the "Company") (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for ...
Background Severe aortic stenosis (AS) is commonly associated with advanced cardiac damage, including right ventricular dysfunction (RVD), pulmonary hypertension (PH) and tricuspid regurgitation (TR), ...
Savara said the Food and Drug Administration does not plan to convene an advisory committee to review its biologics license application for a potential lung disease treatment. The biopharmaceutical ...
Pulmonx Corporation (NASDAQ:LUNG) Q4 2025 Earnings Call Transcript March 4, 2026 Pulmonx Corporation beats earnings ...
The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
Nearly 1 in 3 patients with connective tissue disease-associated interstitial lung disease will develop progressive pulmonary fibrosis.
Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...
Global Capnography Equipment Market OverviewThe global capnography equipment market is anticipated to grow at a steady pace with an estimated compound annual growth rate of around 5% over the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results